Close Menu

Genetics and Public Policy Center

NEW YORK (GenomeWeb News) – Blood samples that are left over from newborn screening tests offer a treasure trove of research materials for scientists seeking to uncover the role of genes in diseases and health, and the science community should be pushing for policies that promote their use in res

A Cogent Research study of 1,000 US residents found decreasing interest in pharmacogenomics applications compared to previous years, while the number of respondents who fear that their genomic data could be used against them is on the rise.

The results of one study indicate that "there is room to improve the clarity of the information provided to customers in their personal genetic test result reports and the way the information is being delivered to them."

The NIH is hoping that its Genetic Testing Registry will serve as a resource for the public to learn about tests and locate laboratories that offer such tests, as well as facilitate data sharing among researchers. But since participation in the registry is voluntary, how will NIH convince test makers to participate?

The center will study public attitudes about large-scale population-based gene/environment interactions.

Paired Ends: Aug 25, 2009


Christian Henry, Kathy Hudson, Joan Scott, Thomas Caskey, Carl Gordon, Pete Dominici, David Barker, Lynne Kielhorn

Though none are on the books yet, state false advertising laws could apply to gene tests.

In a paper published in Public Health Genomics, GPPC emphasizes that the need for a genetic test registry has been exacerbated by the rapid growth in the availability of genetic tests and the marketing of these products directly to consumers.

The GPPC officials said that tests should be listed with their information on clinical and analytical validity, clinical utility, and other points in a registry with NIH or FDA.

A California bill, sponsored by 23andMe, would essentially exempt certain personal genomics firms from having to meet CLIA standards, but would create new requirements for the nascent industry. Privacy groups and members of the personalized medicine community are concerned that the bill doesn't go far enough to protect consumers' genetic information or ensure the accuracy of these tests.


Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.